OBI-3424 (Prodrug)

OBI-3424 (Prodrug)

AKR1C3 Enzyme Prodrug

OBI-3424 is a first-in-class novel prodrug that can selectively act on a variety of cancers with overexpression of Aldo-keto reductase family 1 member C3 (AKR1C3). OBI-3424 has been granted Orphan Drug Designation (ODD) for the treatment of hepatocellular carcinoma (HCC) and acute lymphocytic leukemia (ALL).

The Phase I/II dose escalation study and evaluation of the dose limiting toxicity is being conducted at the University of Texas MD Anderson Cancer Center and Ohio University, The James Cancer Hospital and Solove Research Institute.

In May 2020, OBI published an abstract at the American Society of Clinical Oncology (ASCO) virtual annual meeting, presenting the OBI-3424 Phase I/II clinical trial process and preliminary data.

OBI-3424 cohort expansion phase will use an immunohistochemistry (IHC) method to screen patients with high AKR1C3 expression as recruitment population.